Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Besponsa

(inotuzumab ozogamicin)

inotuzumab ozogamicin 0.9 MG Injection [Besponsa]

Dosage & administration

* Pre-medicate with a corticosteroid, antipyretic, and antihistamine prior to all infusions.
* Dosing regimens for Cycle 1 and subsequent cycles, depending on the response to treatment, are shown below. See full prescribing information for dosing details.

	Day 1	Day 8	Day 15
* For patients who achieve a CR or a CRi, and/or to allow for recovery from toxicity, the cycle length may be extended up to 28 days (i.e., 7-day treatment-free interval starting on Day 21).
Dosing regimen for Cycle 1
All patients:
Dose	0.8 mg/m2	0.5 mg/m2	0.5 mg/m2
Cycle length	21 days *
Dosing regimen for subsequent cycles depending on response to treatment
Patients who have achieved a CR or CRi:
Dose	0.5 mg/m2	0.5 mg/m2	0.5 mg/m2
Cycle length	28 days
Patients who have not achieved a CR or CRi:
Dose	0.8 mg/m2	0.5 mg/m2	0.5 mg/m2
Cycle length	28 days

* See full prescribing information for instructions on reconstitution of lyophilized powder, and preparation and administration of reconstituted drug.

Besponsa clinical details

Mechanism of Action (MOA)

Dosing & Administration

Clinical Trials

Efficacy

Safety Profile

drug label

Besponsa prescribing information

Have more Besponsa questions?

Submit MSL Request

Learn More

Need to report a Besponsa issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Besponsa Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

NOT PROVIDED BY BRANDComplete Coverage Authorization appeals

Coverage Authorization Appeal

Formulary Exception Letter

Learn More

Benefits investigation

Pfizer Oncology Together Form

Pfizer Oncology Together Form - Spanish

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Besponsa Financial assistance options

Co-pay savings program

commercial only

Pfizer Oncology Together Form

Pfizer Oncology Together Form - Spanish

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Pfizer Oncology Together Form

Pfizer Oncology Together Form - Spanish

Pfizer Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Besponsa Patient education

Getting started on Besponsa

NOT PROVIDED BY BRANDInstructions For Use: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL)